Morgan Stanley
MBX icon

Morgan Stanley’s MBX Biosciences MBX Stock Holding History

Morgan Stanley’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.7M Buy
248,558
+216,996
+688% +$7.58M ﹤0.01% 3440
2026
Q1 		$942K Sell
31,562
-27,464
-47% -$934K ﹤0.01% 5172
2025
Q4 		$1.86M Buy
59,026
+14,158
+32% +$344K ﹤0.01% 4860
2025
Q3 		$785K Buy
44,868
+20,860
+87% +$279K ﹤0.01% 5282
2025
Q2 		$274K Sell
24,008
-90,602
-79% -$923K ﹤0.01% 5726
2025
Q1 		$846K Buy
114,610
+90,775
+381% +$960K ﹤0.01% 5086
2024
Q4 		$439K Buy
+23,835
New +$508K ﹤0.01% 5475

Other funds holding MBX

Frazier Life Sciences Management
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
NEA Management Company
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Paradigm Biocapital Advisors
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return
Deep Track Capital
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Polar Capital Holdings
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Morgan Stanley's MBX Position: Q2 2026 in Review

Morgan Stanley increased its MBX Biosciences (MBX) stake by 688% in Q2 2026, buying an estimated $7.58M and bringing the position to 248,558 shares worth $13.7M. The position accounts for ﹤0.01% of the portfolio, ranked #3440.

Morgan Stanley first reported a position in MBX in Q4 2024 and has held it in 7 quarters since. 172 funds tracked by Wall St. Rank hold MBX as of Q2 2026.

  • Morgan Stanley held 248,558 shares of MBX Biosciences worth $13.7M as of Q2 2026.
  • Morgan Stanley bought 216,996 MBX Biosciences shares in Q2 2026, an estimated $7.58M.
  • MBX Biosciences made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #3440 holding.
  • Morgan Stanley first reported a position in MBX Biosciences in Q4 2024 and has held it in 7 quarters since.
  • 172 funds tracked by Wall St. Rank held MBX Biosciences as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.